Oral Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
figureposted on 2021-01-18, 11:24 authored by Adis journals on behalf of, Richard E. Pratley, Matthew J. Crowley, Mette Gislum, Christin L. Hertz, Thomas B. Jensen, Kamlesh Khunti, Ofri Mosenzon, John B. Buse
Article full text
The above summary slide and graphical abstract represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.